Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Allogeneic (γ/δ) BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies

NCT07679919 is registered in ClinicalTrials.gov with Luminary Therapeutics as lead sponsor.

NCT NCT07679919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07679919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Allogeneic (γ/δ) BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Lead sponsor
Luminary Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
April 30, 2029
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, hairy cell leukemia, multiple myeloma, non-hodgkin lymphoma